Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients

Published:2021-06-16 Issue:4 Volume:74 Page:2304-2306
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Meszaros Magdalena¹^ORCID,Truchi Régine²³,Ouzan Denis⁴,Tran Albert²³,Bourlière Marc⁵,Pageaux Georges‐Philippe¹

Affiliation:

1. Hépato‐GastroentérologieHôpital Saint‐Eloi Montpellier France

2. Université Côte d’Azur Nice France

3. Digestive Center CHU de Nice Nice France

4. Unité d'Hépatologie Institut Arnault Tzanck Saint Laurent du Var France

5. Service d'Hépatologie Hôpital Saint Joseph Marseille France

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31909

Reference5 articles.

1. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

2. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts

3. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

4. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

5. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

2. Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C;Revista Española de Quimioterapia;2024-04-19

3. Unlocking hope: Hepatitis C Virus re-treatment strategy for patients with active hepatocellular carcinoma;JHEP Reports;2024-04

4. Sofosbuvir/velpatasvir/voxilaprevir;Reactions Weekly;2022-11-12

5. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection;Journal of Hepatology;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3